Suspect pulmonary fibrosis

—a common threat across a wide range of interstitial lung diseases (ILDs), including connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Pulmonary fibrosis can become a key driver of irreversible harm and early mortality, and calls for urgent identification and intervention.^1–4

Three patients holding lung scan results in their hands.

DISCOVER THE TRUE IMPACT OF FIBROTIC ILDs

Maximize confidence in ILD diagnosis

Diagnosis of ILD

For at-risk patients, HRCT should be evaluated at the first suspicion of fibrotic ILD involvement.^1,5–8

Maximize confidence in ILD diagnosis

Inform your management decisions

Early and regular monitoring

Time is of the essence when progressive fibrosing ILD is suspected.⁹

Inform your management decisions

Why is pulmonary fibrosis a critical threat?

Critical threat of fibrotic ILDs

Pulmonary fibrosis is a critical threat across a broad range of ILDs.^1-4

Why is pulmonary fibrosis a critical threat?

IMAGING ATLAS OF ILDs

Improve your ability to diagnose fibrotic ILDs.

This imaging atlas can assist your ILD diagnosis, helping you to recognize key clues and characteristics on HRCT and histopathology.

Download the imaging atlas of HRCT scans

ILD signs and symptoms

Initial evaluation for ILDs

Identifying pulmonary fibrosis early may improve burden of disease.^9–12

ILD signs and symptoms

HRCT, the gold standard

HRCT imaging of pulmonary fibrosis

High-resolution computed tomography is essential for accurate diagnoses of fibrotic ILDs.¹³

HRCT, the gold standard

Explore intervention options for your ILD patients

Interventions for ILDs

Early treatment is essential in IPF and could positively impact progression^14–16

Explore intervention options for your ILD patients

Learn how best to break bad news to your patients

SPIKES model: breaking bad news to your patients

Professor Walter Baile takes us through the SPIKES mode on how to structure difficult conversations

Learn how best to break bad news to your patients

Impact of acute exacerbation of ILD

Acute exacerbation of ILD

A threat that could strike at any time.^17–21

Impact of acute exacerbation of ILD

Identify ILD in the real world

ILD patient cases for evaluation and diagnosis

Download our patient cases: medical histories of representative patients

Identify ILD in the real world

Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.
Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-370.
Caban JJ, Yao J, Bagci U, Mollura DJ. Monitoring pulmonary fibrosis by fusing clinical, physiological, and computed tomography features. Conf Proc IEEE Eng Med Biol Soc. 2011;6216-6219.
Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, on behalf of the IPF Consensus Working Group. Eur Resp J. 2018;51:1800692.
Theodore AC, Tseng C-H, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. 2012;142(3):614–621.
Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med. 2019;200:1258–1266.
Hoffmann-Vold AM, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatology. 2020b;2:e71–e83.
Asano Y, Jinnin M, Kawaguchi Y, et al. Diagnostic criteria, severity classification and guidelines of systemic sclerosis: Guideline of SSc. J Dermatol. 2018;45, 633–691.
Cottin V, Hirani N, Hotchkin D, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.
Chaudhuri N, Spencer L, Greaves M, et al. A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre. J Clin Med. 2016;5(66):1–9.
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc–ILD). Respir Res. 2019a;20(1):13.
Wong AW, Ryerson C, Guler S. Progression of fibrosing interstitial lung disease. Respir Res. 2020:29;21(1):32.
Brauner M, et al. Imagerie des pneumopathies infiltrantes diffuses. Press Med. 2010;39:73–84.
Maher TM, Molina-Molina M, Russell AM, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med. 2017;17(1):124.
Molina-Molina M, Aburto M, Acosta O, et al. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis. Exp Rev Resp Med. 2018;12(7):537–539.
Robalo-Cordeiro C, Campos P, Carvalho L, et al. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence. Rev Port Pneumol. 2017;23(5):287–293.
Kolb M, Bondue B, Pesci A, et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):pii:180071.
Song JW, Hong S-B, Lim C-M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–363.
Song JW, Lee HK, Lee CK, et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):103-112.
Tomiyama F, Watanabe R, Ishii T, et al. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis. Tohoku J. Exp. Med. 2016;239, 297–305.
Okamoto M, Fujimoto K, Sadohara J, et al. A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. Respiratory Investigation. 2016;54, 445–453.